Progress of infant obesity is associated with higher aspartyl-glutamate and alanyl-aspartate in maternal and neonatal blood
Frontiers in Public Health · 2025
DOI: 10.3389/fpubh.2025.1623604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2025. Verfasst von Yuanying Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynaecology, Peking University Third Hospital, Beijing,…. Hauptthemen laut MEDLINE: Fetal Blood, Pediatric Obesity, Obesity. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Objective
Neonatal obesity may be associated with the intra-uterine environment during pregnancy. The objective of this study was to evaluate the risk of neonatal obesity born from the mothers with abnormal glucose and lipid metabolism.
Methods
Twenty neonates born from maternal glucose and lipid metabolism disorders and developed obesity at 6 months of age were enrolled as study group, and 20 neonates without obesity were included as control group. Non-targeted metabolomic analysis was performed in maternal serum during pregnancy and neonatal cord blood at birth to identify differential metabolites.
Results
The concentrations of aspartyl-glutamate and alanyl-aspartate in maternal serum progressively rise steadily as gestational age advances, peaking in umbilical cord blood. Additionally, at each stage of pregnancy (early, middle, and late), the levels in both maternal serum and umbilical cord blood are significantly higher in the obese group than in the non-obese group. Their mechanisms of action may be associated with pathways involving immune-inflammatory regulation, energy metabolism, and gut microbiota modulation. Their mechanisms of action may be associated with pathways involving immune-inflammatory regulation, energy metabolism, and gut microbiota modulation.
Conclusion
Through the analysis of maternal blood during pregnancy and umbilical cord blood, this study putatively identified some differential metabolites associated with neonatal obesity. In the future, it is expected that analyzing maternal blood or umbilical cord blood at birth could help predict potential infant obesity risks, enabling more dietary guidance and interventions during infancy to reduce the risk of obesity later in life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynaecology, Peking University Third Hospital, Beijing, China.
- Department of Community Health Sciences, UIC School of Public Health, Chicago, IL, United States.
- Department of Pediatric, Peking University Third Hospital, Beijing, China.
- Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Liu, Y., Ma, M., Yu, Y., Yang, C., Yang, J., Han, T., & Wang, Y. (2025). Progress of infant obesity is associated with higher aspartyl-glutamate and alanyl-aspartate in maternal and neonatal blood. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1623604
Vancouver
Liu Y, Ma M, Yu Y, Yang C, Yang J, Han T, et al. Progress of infant obesity is associated with higher aspartyl-glutamate and alanyl-aspartate in maternal and neonatal blood. Frontiers in Public Health. 2025. doi:10.3389/fpubh.2025.1623604
BibTeX
@article{Liu2025,
author = {Liu, Yuanying and Ma, Mingyue and Yu, Yanhong and Yang, Chunyuan and Yang, Jianling and Han, Tongyan and Wang, Yongqing},
title = {Progress of infant obesity is associated with higher aspartyl-glutamate and alanyl-aspartate in maternal and neonatal blood},
journal = {Frontiers in Public Health},
year = {2025},
doi = {10.3389/fpubh.2025.1623604}
}
EUVIMED